IL6 and neoplasm: When combined with anti-PD-1 therapy, ES@CuO significantly increased tumor-infiltrating lymphocytes and upregulated key cytokines (IL-6, TNF-α, IFN-γ), confirming its ability to reprogram the immunosuppressive tumor microenvironment via cuproptosis.